{"text_format":"3","workbook":"xls","n_sheets":3,"sheets":["Sheet1","Sheet2","Sheet3"],"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Sheet1","index":0,"n_rows":58,"n_cols":6,"rows_kept":58,"merged":[[0,0,0,5],[1,0,2,0],[1,1,1,2],[1,3,2,3],[1,4,2,4],[1,5,2,5],[57,0,57,5]],"flags":["formulas_cached_only"]}
["Supplementary Table S1 \nRelationship between PPARγ expression and clinicopathological characteristicsin WDLPS patients(n=28)."]
["characteristics","PPARγ expression",null,"Total\n(n=28)","χ2","p Value"]
[null,"High(n=14)","Low(n=14)"]
["Age(years)"]
["<60",8,6,14,0.1429,0.7055]
["≥60",6,8,14]
["Gender"]
["Male",7,4,11,0.5989,0.4389]
["Female",7,10,17]
["Inpatient days(day)"]
["≤13",9,9,18,0.1556,0.6932]
[">13",5,5,10]
["Other complications"]
[0,10,10,20,0.175,0.6757]
[1,4,4,8]
["History of surgeries"]
[0,5,8,13,0.5744,0.4485]
[1,9,6,15]
["BMI"]
["< 25",10,14,24,2.625,0.1052]
["≥ 25",4,0,4]
["Number of primary tumors"]
["Solitary",11,13,24,0.2917,0.5891]
["Multiple",3,1,4]
["Surgical method (R0/R1)"]
["RO",10,13,23,0.9739,0.3236]
["R1",4,1,5]
["Surgery duration (min)"]
["≤180",7,7,14,0.1429,0.7055]
[">180",7,7,14]
["Peroperative bleeding(ml)"]
["≤600",6,11,17,5.3904,0.0203]
[">600",8,3,11]
["Postoperative complications"]
[0,14,13,27,0,1]
[1,0,1,1]
["Tumor size(T)"]
["T1/T2",3,0,3,1.4933,0.2217]
["T3/T4",11,14,25]
["Lymph node metastasis(N)"]
[0,14,14,28,"-","-"]
[1,0,0,0]
["Distant metastasis(M)"]
[0,11,13,24,0.2917,0.5891]
[1,3,1,4]
["MDM2 expression"]
["Negative",8,8,16,0.1458,0.7025]
["Positive",6,6,12]
["CKD4 expression"]
["Negative",0,2,2,0.5385,0.463]
["Positive",14,12,26]
["MDM2 gene amplification(%)"]
["≤80",9,13,22,1.9091,0.1671]
[">80",5,1,6]
["Chemoradiotherapy"]
[0,14,14,28,"-","-"]
[1,0,0,0]
["Chi-square analysis demonstrated that PPARγ expression in WDLPS patients showed no significant correlation with any clinicopathological characteristics, including age, gender, length of hospital stay, comorbidities, history of unrelated surgery, BMI, number of primary tumors, surgical margin status (R0/R1), intraoperative blood loss, severe postoperative complications, TNM stage, MDM2 protein expression, CDK4 expression, operation time, percentage of MDM2 gene amplification, and receipt of adjuvant chemoradiotherapy."]

{"sheet":"Sheet2","index":1,"n_rows":0,"n_cols":0,"rows_kept":0,"flags":["formulas_cached_only"]}

{"sheet":"Sheet3","index":2,"n_rows":0,"n_cols":0,"rows_kept":0,"flags":["formulas_cached_only"]}